Does the media prefer CSTL or HTFL?

In the previous week, Heartflow had 3 more articles in the media than Castle Biosciences. MarketBeat recorded 6 mentions for Heartflow and 3 mentions for Castle Biosciences. Heartflow's average media sentiment score of 0.92 beat Castle Biosciences' score of 0.87 indicating that Heartflow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heartflow 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PGNY or CSTL?

In the previous week, Progyny and Progyny both had 3 articles in the media. Progyny's average media sentiment score of 1.33 beat Castle Biosciences' score of 0.87 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, WGS or CSTL?

GeneDx has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 4.69 -$21.02M -$2.68 N/A Castle Biosciences $344.23M 2.12 -$24.16M -$0.44 N/A

Does the media prefer WGS or CSTL?

In the previous week, GeneDx had 28 more articles in the media than Castle Biosciences. MarketBeat recorded 31 mentions for GeneDx and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.87 beat GeneDx's score of 0.09 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 4 Very Positive mention(s) 0 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Castle Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CSTL or SNDA?

In the previous week, Castle Biosciences had 2 more articles in the media than Sonida Senior Living. MarketBeat recorded 3 mentions for Castle Biosciences and 1 mentions for Sonida Senior Living. Castle Biosciences' average media sentiment score of 0.87 beat Sonida Senior Living's score of 0.00 indicating that Castle Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sonida Senior Living 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Castle Biosciences (CSTL) Competitors

$24.11 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$23.97 -0.14 (-0.56%)

As of 07/2/2026 07:34 PM Eastern

Compare

CSTL vs. HTFL, PGNY, SGRY, WGS, and SNDA

Should you buy Castle Biosciences stock or one of its competitors? MarketBeat compares Castle Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Castle Biosciences include Heartflow (HTFL), Progyny (PGNY), Surgery Partners (SGRY), GeneDx (WGS), and Sonida Senior Living (SNDA). These companies are all part of the "healthcare" industry.

How does Castle Biosciences compare to Heartflow?

Castle Biosciences (NASDAQ:CSTL) and Heartflow (NASDAQ:HTFL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Castle Biosciences currently has a consensus target price of $42.43, suggesting a potential upside of 75.98%. Heartflow has a consensus target price of $37.00, suggesting a potential upside of 32.28%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Castle Biosciences is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

92.6% of Castle Biosciences shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 7.7% of Heartflow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Castle Biosciences has higher revenue and earnings than Heartflow. Castle Biosciences is trading at a lower price-to-earnings ratio than Heartflow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	2.12	-$24.16M	-$0.44	N/A
Heartflow	$176.03M	13.70	-$116.79M	-$3.11	N/A

In the previous week, Heartflow had 3 more articles in the media than Castle Biosciences. MarketBeat recorded 6 mentions for Heartflow and 3 mentions for Castle Biosciences. Heartflow's average media sentiment score of 0.92 beat Castle Biosciences' score of 0.87 indicating that Heartflow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heartflow	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Castle Biosciences has a net margin of -3.78% compared to Heartflow's net margin of -58.42%. Heartflow's return on equity of 0.00% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Heartflow	-58.42%	N/A	-20.02%

Summary

Castle Biosciences beats Heartflow on 9 of the 15 factors compared between the two stocks.

How does Castle Biosciences compare to Progyny?

Progyny (NASDAQ:PGNY) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Progyny has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Progyny has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.84	$58.52M	$0.77	39.25
Castle Biosciences	$344.23M	2.12	-$24.16M	-$0.44	N/A

In the previous week, Progyny and Progyny both had 3 articles in the media. Progyny's average media sentiment score of 1.33 beat Castle Biosciences' score of 0.87 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has a net margin of 5.23% compared to Castle Biosciences' net margin of -3.78%. Progyny's return on equity of 13.34% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Castle Biosciences	-3.78%	-2.77%	-2.30%

94.9% of Progyny shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Progyny currently has a consensus target price of $29.92, suggesting a potential downside of 1.00%. Castle Biosciences has a consensus target price of $42.43, suggesting a potential upside of 75.98%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Castle Biosciences is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Progyny beats Castle Biosciences on 12 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Surgery Partners?

Surgery Partners (NASDAQ:SGRY) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Castle Biosciences has lower revenue, but higher earnings than Surgery Partners. Castle Biosciences is trading at a lower price-to-earnings ratio than Surgery Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.34B	0.67	-$77.90M	-$0.60	N/A
Castle Biosciences	$344.23M	2.12	-$24.16M	-$0.44	N/A

92.6% of Castle Biosciences shares are held by institutional investors. 2.0% of Surgery Partners shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Castle Biosciences had 2 more articles in the media than Surgery Partners. MarketBeat recorded 3 mentions for Castle Biosciences and 1 mentions for Surgery Partners. Castle Biosciences' average media sentiment score of 0.87 beat Surgery Partners' score of 0.64 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Surgery Partners	Positive
Castle Biosciences	Positive

Surgery Partners currently has a consensus price target of $22.18, suggesting a potential upside of 28.74%. Castle Biosciences has a consensus price target of $42.43, suggesting a potential upside of 75.98%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Surgery Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Surgery Partners has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Surgery Partners has a net margin of -2.28% compared to Castle Biosciences' net margin of -3.78%. Surgery Partners' return on equity of 1.04% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Castle Biosciences	-3.78%	-2.77%	-2.30%

Summary

Castle Biosciences beats Surgery Partners on 9 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to GeneDx?

GeneDx (NASDAQ:WGS) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

In the previous week, GeneDx had 28 more articles in the media than Castle Biosciences. MarketBeat recorded 31 mentions for GeneDx and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.87 beat GeneDx's score of 0.09 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	4 Very Positive mention(s)	0 Positive mention(s)	26 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Castle Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Castle Biosciences has a net margin of -3.78% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Castle Biosciences	-3.78%	-2.77%	-2.30%

GeneDx has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

GeneDx has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.69	-$21.02M	-$2.68	N/A
Castle Biosciences	$344.23M	2.12	-$24.16M	-$0.44	N/A

61.7% of GeneDx shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 25.2% of GeneDx shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GeneDx currently has a consensus price target of $87.43, indicating a potential upside of 29.50%. Castle Biosciences has a consensus price target of $42.43, indicating a potential upside of 75.98%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Castle Biosciences is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

GeneDx beats Castle Biosciences on 9 of the 17 factors compared between the two stocks.

How does Castle Biosciences compare to Sonida Senior Living?

Castle Biosciences (NASDAQ:CSTL) and Sonida Senior Living (NYSE:SNDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

In the previous week, Castle Biosciences had 2 more articles in the media than Sonida Senior Living. MarketBeat recorded 3 mentions for Castle Biosciences and 1 mentions for Sonida Senior Living. Castle Biosciences' average media sentiment score of 0.87 beat Sonida Senior Living's score of 0.00 indicating that Castle Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sonida Senior Living	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Castle Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Sonida Senior Living has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Castle Biosciences has a net margin of -3.78% compared to Sonida Senior Living's net margin of -24.15%. Castle Biosciences' return on equity of -2.77% beat Sonida Senior Living's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
Sonida Senior Living	-24.15%	-36.98%	-7.08%

Castle Biosciences presently has a consensus target price of $42.43, suggesting a potential upside of 75.98%. Sonida Senior Living has a consensus target price of $41.25, suggesting a potential downside of 2.01%. Given Castle Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Castle Biosciences is more favorable than Sonida Senior Living.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sonida Senior Living	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 87.6% of Sonida Senior Living shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 39.3% of Sonida Senior Living shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Castle Biosciences has higher earnings, but lower revenue than Sonida Senior Living. Castle Biosciences is trading at a lower price-to-earnings ratio than Sonida Senior Living, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	2.12	-$24.16M	-$0.44	N/A
Sonida Senior Living	$381.14M	5.23	-$70.78M	-$5.83	N/A

Summary

Castle Biosciences beats Sonida Senior Living on 13 of the 17 factors compared between the two stocks.

Get Castle Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSTL vs. The Competition

Export

Metric	Castle Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$731.26M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-54.80	21.61	28.02	24.70
Price / Sales	2.12	339.42	538.82	97.75
Price / Cash	21.66	147.12	49.26	57.09
Price / Book	1.49	8.66	10.96	6.46
Net Income	-$24.16M	$23.81M	$3.57B	$337.01M
7 Day Performance	-0.78%	3.39%	2.12%	1.69%
1 Month Performance	14.75%	10.81%	5.25%	3.81%
1 Year Performance	18.86%	62.61%	33.29%	23.90%

Castle Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSTL Castle Biosciences	3.305 of 5 stars	$24.11 flat	$42.43 +76.0%	+18.9%	$731.26M	$344.23M	N/A	540
HTFL Heartflow	3.5463 of 5 stars	$29.78 -14.6%	$37.00 +24.3%	N/A	$2.57B	$191.42M	N/A	699	News Coverage Analyst Upgrade
PGNY Progyny	3.2739 of 5 stars	$28.89 +0.1%	$29.92 +3.6%	+40.9%	$2.26B	$1.29B	37.52	310	Positive News
SGRY Surgery Partners	3.0265 of 5 stars	$16.51 -0.3%	$22.18 +34.4%	-22.2%	$2.16B	$3.31B	N/A	16,000	Options Volume Gap Down
WGS GeneDx	3.9657 of 5 stars	$68.80 -0.5%	$87.43 +27.1%	-26.3%	$2.04B	$442.68M	N/A	1,300	Trending News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSTL) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Competitors

CSTL vs. HTFL, PGNY, SGRY, WGS, and SNDA

How does Castle Biosciences compare to Heartflow?

Summary

How does Castle Biosciences compare to Progyny?

Summary

How does Castle Biosciences compare to Surgery Partners?

Summary

How does Castle Biosciences compare to GeneDx?

Summary

How does Castle Biosciences compare to Sonida Senior Living?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Competitors

CSTL vs. HTFL, PGNY, SGRY, WGS, and SNDA

How does Castle Biosciences compare to Heartflow?

Do analysts rate CSTL or HTFL?

Do insiders and institutionals have more ownership in CSTL or HTFL?

Which has higher earnings and valuation, CSTL or HTFL?

Does the media prefer CSTL or HTFL?

Is CSTL or HTFL more profitable?

Summary

How does Castle Biosciences compare to Progyny?

Which has more risk & volatility, PGNY or CSTL?

Which has preferable earnings & valuation, PGNY or CSTL?

Does the media favor PGNY or CSTL?

Is PGNY or CSTL more profitable?

Do institutionals and insiders hold more shares of PGNY or CSTL?

Do analysts recommend PGNY or CSTL?

Summary

How does Castle Biosciences compare to Surgery Partners?

Which has higher earnings & valuation, SGRY or CSTL?

Do institutionals & insiders have more ownership in SGRY or CSTL?

Does the media refer more to SGRY or CSTL?

Do analysts prefer SGRY or CSTL?

Which has more risk and volatility, SGRY or CSTL?

Is SGRY or CSTL more profitable?

Summary

How does Castle Biosciences compare to GeneDx?

Does the media prefer WGS or CSTL?

Is WGS or CSTL more profitable?

Which has more risk & volatility, WGS or CSTL?

Which has stronger earnings & valuation, WGS or CSTL?

Do institutionals and insiders believe in WGS or CSTL?

Do analysts prefer WGS or CSTL?

Summary

How does Castle Biosciences compare to Sonida Senior Living?

Does the media favor CSTL or SNDA?

Which has more risk & volatility, CSTL or SNDA?

Is CSTL or SNDA more profitable?

Do analysts recommend CSTL or SNDA?

Do institutionals & insiders hold more shares of CSTL or SNDA?

Which has preferable earnings and valuation, CSTL or SNDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools